Literature DB >> 17714576

The comparative effects of sevoflurane vs. isoflurane on cerebrovascular carbon dioxide reactivity in patients with hypertension.

Y Kadoi1, S Saito, K Takahashi.   

Abstract

BACKGROUND: Sevoflurane has been shown to have different effects on cerebrovascular CO(2) reactivity in comparison with isoflurane. In this study, the comparative effects of sevoflurane vs. isoflurane on cerebrovascular CO(2) reactivity were examined in patients with hypertension.
METHODS: Fifty patients, 30 hypertensive and 20 normotensive, were included in this study. The 30 hypertensive patients were divided into two groups: sevoflurane and isoflurane. Patients with controlled hypertension (n= 9 in each of the two groups) were those with normal blood pressure levels (systolic blood pressure below 139 mmHg). Patients with uncontrolled hypertension (n= 6 in each of the two groups) were those with high blood pressure levels despite medication (systolic blood pressure above 160 mmHg). Anesthesia was maintained with either 1.0 minimum alveolar concentration (MAC) of sevoflurane or 1.0 MAC of isoflurane in 33% oxygen and 67% nitrous oxide. A 2.5-MHz pulsed transcranial Doppler probe was attached to the patient's head at the right temporal window for continuous measurement of the mean blood flow velocity in the middle cerebral artery (V(mca)). After establishing baseline values of V(mca) and cardiovascular hemodynamics, the end-tidal CO(2) was increased by decreasing the ventilatory frequency by 2-5 breaths per minute.
RESULTS: Values of the absolute and relative CO(2) reactivity in the sevoflurane groups were lower than those in the isoflurane groups. There were no significant intra-group differences in the absolute and relative CO(2) reactivity within the sevoflurane and isoflurane groups.
CONCLUSIONS: Our findings suggest that, in hypertensive patients, the control of cerebral blood flow by altering the pressure of arterial CO(2) (P(a)co(2)) can be more effectively achieved during isoflurane rather than sevoflurane anesthesia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17714576     DOI: 10.1111/j.1399-6576.2007.01422.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  6 in total

1.  Adequacy of control of preoperative hypertension can affect landiolol-induced hemodynamic changes in elderly patients during emergence from anesthesia.

Authors:  Yuji Kadoi; Tatsuo Horiuchi; Shinya Uchida; Shigeru Saito
Journal:  J Anesth       Date:  2011-01-14       Impact factor: 2.078

Review 2.  Pathophysiological and clinical considerations in the perioperative care of patients with a previous ischaemic stroke: a multidisciplinary narrative review.

Authors:  Jatinder S Minhas; William Rook; Ronney B Panerai; Ryan L Hoiland; Phil N Ainslie; Jonathan P Thompson; Amit K Mistri; Thompson G Robinson
Journal:  Br J Anaesth       Date:  2019-12-06       Impact factor: 9.166

3.  Differential effects of hyperventilation on cerebral blood flow velocity after tourniquet deflation during sevoflurane, isoflurane, or propofol anesthesia.

Authors:  Hiroshi Hinohara; Yuji Kadoi; Masanobu Ide; Masataka Kuroda; Shigeru Saito; Akio Mizutani
Journal:  J Anesth       Date:  2010-06-01       Impact factor: 2.078

Review 4.  Perioperative control of hypertension: when will it adversely affect perioperative outcome?

Authors:  John W Sear
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

5.  Effects of landiolol, a short-acting beta-1 blocker, on hemodynamic variables during emergence from anesthesia and tracheal extubation in elderly patients with and without hypertension.

Authors:  Masumi Miyazaki; Yuji Kadoi; Shigeru Saito
Journal:  J Anesth       Date:  2009-11-18       Impact factor: 2.078

6.  Evaluation of cerebrovascular carbon dioxide reactivity in patients with diabetes mellitus under sedative doses of propofol.

Authors:  Chikara Kawauchi; Yuji Kadoi; Hiroshi Hinohara; Fumio Kunimoto; Shigeru Saito
Journal:  J Anesth       Date:  2008-11-15       Impact factor: 2.078

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.